Allergy Diagnostics And Therapeutics Market Report

Allergy Diagnostics And Therapeutics Market Analysis By Product (Instruments, Consumables, Services), By Allergen Type (Food, Inhaled, Drug), By End-use (Academic Research Institutes, Hospitals, Diagnostic Laboratories), By Test (In Vivo, In Vitro), By Drug Class (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Decongestants, Immunomodulators, Autoinjectable Epinephrine, Immunotherapy) And Segment Forecasts To 2022

  • Published Date: Jan, 2016
  • Base Year for Estimate: 2015
  • Report ID: 978-1-68038-701-8
  • Format: Electronic (PDF)
  • Historical Data: 2013-2015
  • Number of Pages: 131

Industry Insights

The global allergy diagnostics and therapeutics market size was valued at USD 25,752.6 million in 2014. Increasing incidences of allergic diseases coupled with demand for in vitro diagnostic blood test is posed to drive the industry growth in coming years. According to estimates published by the World Health Organization (WHO), around 40 million patients were affected by inhaled allergies in 2012, in the U.S. alone and the number is expected to grow over the forecast period contributing towards the adoption of diagnostics globally.

Allergy diagnostics product penetration & future growth opportunities, by allergen type

Allergy diagnostics

Furthermore, factors such as changing lifestyle, increasing indoor and outdoor pollution, dietary habits, and urbanization contribute to the increasing incidences of allergic conditions. The introduction of technologically advanced diagnostic and therapeutic products which offers highly sensitive and accurate results is expected to boost the market growth over the forecast period.

Type of Allergen Insights

Growing global incidences of respiratory allergies and asthma are responsible for the dominance of inhaled allergen segment as of 2014. This segment is expected to grow at fastest rate owing to, the increasing demand for allergy testing and introduction of specific allergen for the detection of allergy. Drug allergies segment is expected to grow at over 11.0% during the forecast period.

Test Type Insights

In vivo test, owing to associated benefits such as ease of use, time efficiency, wider availability and sensitivity for clinically valid allergies held over 51.0% of share in terms of revenue in 2014. Skin prick test accounted for relatively larger revenue share as of 2014 owing to greater adoption by healthcare professionals and patients. In addition, rising applicability in food allergy detection, specific IgE-mediated allergy testing is further expected to provide growth platform to this market.

In vitro test segment is expected to grow lucratively in coming years owing to increasing demand for less invasive diagnostic methods, rising lab automation, coupled with highly sensitive & accurate results. Industry players are concentrating in providing allergy specific solutions, accurate result oriented devices in a vain to capitalize market growth.

Product Insights

Product segment includes instruments, consumables, and services. Consumables segment dominated the overall industry in 2014 in terms of revenue share at over 57.0% as they are an indispensable component in allergy detection. Technological advancements such as allergen microarray kits which are more sensitive and offers individualized patient profiling & monitoring. In addition, the introduction of products such as MeDALL allergen-chip associated with enhanced sensitivity specificity, and faster diagnosis are high impact rendering factor of allergy diagnostics and therapeutics market.

End-use Insights

Allergy diagnostics and therapeutics caters various sectors including academic research studies, hospitals, and diagnostic laboratories. As of 2014, diagnostic laboratories held the largest revenue share of over 50.0% due to extensive utilization of immunoassay tests in allergy diagnosis.

In addition, advancements in screening techniques enabling accurate disease diagnosis and stratification for appropriate treatment is expected to further augment growth opportunities for this segment. Hospital segment is expected to be the fastest growing segment in terms of revenue share due to increasing penetration, supportive government funding, and rising healthcare expenditure.

Therapeutic Drug Class Insights

The global market dominated by antihistamines as of 2014, due to associated benefits with its usage and wide applications in the treatment of allergy diseases. Immunotherapy segment expected to be the fastest growing segment with CAGR of 6.4% owing to increasing demand for sublingual vaccines , extensive drug pipeline, ongoing clinical trials of monoclonal antibodies for the treatment of allergic disorders and growing awareness amongst patients.

Regional Insights

North America dominated the overall industry in terms of revenue in 2014 at over 39.0%. Higher incidence of respiratory allergic disorders, awareness level pertaining to allergy diagnostics and rising adoption of in vitro blood tests are attributing to the largest revenue share of this region. The European market is also expected to show positive growth due to developed pharmaceutical industry and increasing demand for therapeutics. Growing geriatric population and rising incidences of allergic conditions are also contributing to the aforementioned growth.

Asia-Pacific, on the other hand, is expected to be the fastest growing regional industry, by registering CAGR of over 12.0% in coming years due to the presence of high unmet needs, improvising healthcare infrastructure and demand for minimally invasive diagnostic tools from the consumer end.

Competitive Market Share Insights

Some key players in this market include bioMerieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group and Alcon Laboratories.

Pertinent segments are expected to experience lucrative growth primarily owing to, the increasing automation in allergy diagnostics. For instance, in July 2015, Thermo Fisher launched the Phadia 2500E Laboratory System which offers better diagnostic solutions in order to gain a competitive advantage over other players. In addition, participants are now concentrating in providing allergy specific solutions, accurate result oriented devices in order to capitalize on unmet consumer needs.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,250
Multi User (2-5) - $5,250
Enterprise Access - $7,250

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified